Replimune (REPL) Group announced that the U.S. Food and Drug Administration, FDA, has accepted the resubmission of the Biologics License Application, BLA, for RP1 in combination with nivolumab for the treatment of advanced melanoma in patients who progress on an anti-PD-1 containing regimen. The PDUFA date set by the FDA is April 10, 2026 based on a Class II resubmission timeline. “We are pleased the agency has accepted the resubmission of our BLA for RP1,” said Sushil Patel, Ph.D., CEO of Replimune. “RP1 plus nivolumab offers a strong risk benefit profile where there are few options for patients with advanced melanoma, who have progressed on PD-1 based therapy. We look forward to working closely with the agency to expedite this review as much as possible for patients’ benefit.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Replimune announces new ad hoc analysis from IGNYTE phase 2 cohort of RP1
- Intel downgraded, Tesla upgraded: Wall Street’s top analyst calls
- Replimune downgraded to Underweight from Neutral at JPMorgan
- Replimune Group Completes FDA Meeting on RP1 Application
- Replimune says ‘committed’ to working with FDA to determine path forward for RP1